Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer.

ABSTRACT:

Background

Palbociclib is indicated for the treatment of hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC), in combination with endocrine therapy. Emerging real-life data suggest that the efficacy of a palbociclib-based therapy is highly conserved. We report the Institut Curie hospital experience.

Patients and methods

We retrospectively reviewed all patients with HR + HER2- ABC treated with a palbociclib-based therapy as first or second line for ABC, with an initial prescription from November 2016 to December 2018. Clinical, laboratory and imaging data were retrieved from electronic records. Data lock was December 31st, 2019. Descriptive analyses, univariate and multivariate Cox regression analyses were performed.

Results

We included

SUBMITTER: Porte B 

PROVIDER: S-EPMC7695984 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature